CSIMarket
 
Regeneron Pharmaceuticals Inc   (REGN)
 

News




Regeneron*s Odronextamab Faces Regulatory Hurdles as FDA Issues Complete Response Letters, Enrollment Status of Confirmatory Trials the Primary Concern

FDA Approves Praluent for Treating Genetic High Cholesterol in Children, While New Data Shows Encouraging Efficacy in Treating Follicular and Diffuse Large B-cell Lymphomas

EYLEA HD Bolsters Treatment of Sight-Threatening Conditions, While Dupixent*s Approval in Japan Offers a Ray of Hope for Chronic Itching Patients

Dupixent (Dupilumab) SBLA Accepted for FDA Priority Review for COPD with Type 2 Inflammation: A Potential Breakthrough in COPD Treatment

Advancing Treatment Possibilities: Linvoseltamab*s BLA for Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Dupixent Breaks Ground as Japan Approves World*s First Treatment for Chronic Spontaneous Urticaria, Offering Relief and Hope for Sufferers

Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes

Pioneering Research Reveals Potential of Odronextamab and ctDNA in Long-term Prognostication of Diffuse Large B-cell Lymphoma

Revolutionizing Oncology: Regeneron*s Groundbreaking Combination Therapies Show Promise in Ovarian Cancer Treatment while Navigating Financial Challenges

Headline: Regeneron Pharmaceuticals Inc Shows Resilience with Revenue Growth Despite Deterioration in Earnings

Revitalization of Earnings: Major Pharmaceutical Preparations Company Faces -23.76% EPS Decrease in Q3 2023 Earnings Season

revenue Increased substantially at the company all along the April to June 30 2023 interval

Regeneron Pharmaceuticals Inc. Dominates Market Growth with Exhilarating Q1 Profits Surge

Earnings down on soft Revenue at the all along the July to September 30 2022 three months

Sharp fall in EPS at the Regeneron Pharmaceuticals Inc in the second quarter of 2022

Very dynamic growth by REGN over the fiscal first quarter of 2022









Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com